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Aminophospholipids are signaltransducing TREM2 ligands on
apoptotic cells
Keiro Shirotani1,2, Yuma Hori1,2, Ryohei Yoshizaki1, Eri Higuchi1, Marco Colonna3,
Takashi Saito 4, Shoko Hashimoto 5, Takashi Saito 5, Takaomi C. Saido5 &
Nobuhisa Iwata 1,2
Variants of triggering receptor expressed on myeloid cells 2 (TREM2) are associated with an increased
incidence of Alzheimer’s disease, as well as other neurodegenerative disorders. Using a newly
developed, highly sensitive reporter cell model, consisting of Jurkat T cells stably overexpressing a
reporter gene and a gene encoding TREM2DAP12 fusion protein, we show here that TREM2-dependent
signal transduction in response to apoptotic Neuro2a cells is mediated by aminophospholipid ligands,
phosphatidylserine and phosphatidylethanolamine, which are not exposed on the intact cell surface,
but become exposed upon apoptosis. We also show that signal-transducing TREM2 ligands different
from aminophospholipids, which appear to be derived from neurons, might be present in membrane
fractions of mouse cerebral cortex. These results may suggest that TREM2 regulates microglial function
by transducing intracellular signals from aminophospholipids on apoptotic cells, as well as unidentified
ligands in the membranes of the cerebral cortex.
Microglia, which are resident myeloid cells in the brain, provide acute and chronic surveillance of damage- and
pathogen-associated signals as a part of the innate immune system1. The role of microglia in neurodegenerative
disorders associated with chronic inflammation has been investigated extensively. In the Alzheimer’s disease
(AD) brain, for example, reactive microglia are associated with amyloid plaques consisting of aggregated amyloid
β peptide (Aβ)2–4. Aβ stimulates microglia and induces proinflammatory phenotypes that are thought to damage neurons and exacerbate disease progression5,6. On the other hand, microglia have protective roles against
AD through phagocytosis of Aβ and apoptotic neurons7,8. Thus, proper regulation of diverse microglial functions should ameliorate disease progression. Genetic studies have identified several AD-associated risk factors
expressed by microglia9–12. These include triggering receptor expressed on myeloid cells-2 (TREM2)13,14, whose
homozygous mutations were found in certain types of neurodegenerative disorders, such as Nasu-Hakola disease
and frontotemporal dementia-like syndromes15–17. Heterozygous mutations of TREM2 show a high odds ratio
for the onset of AD13,14 as well as the other neurodegenerative disorders18–20. So far, R47H and R62H variants
of TREM2 have been confirmed to present a significant risk for AD21, though other variants have not reached
statistical significance, probably because of their low frequency. In addition, R47H mutation is correlated with
increased tau levels in cerebrospinal fluid22 and increased phosphorylated tau levels around amyloid plaques23 in
AD brains. Elevated expression of TREM2 gene is reported to ameliorate pathological phenotypes in AD models24. These studies highlight that functional alterations of TREM2 due to mutation contribute to the development
of neurodegenerative disorders, possibly by loss of function25,26, and indicate that a better understanding of the
role of TREM2 could provide new insights for drug discovery.
TREM2 is a type I transmembrane protein associated with DNAX-activating protein of 12 kDa (DAP12)
in the transmembrane domain, and DAP12 has an immunoreceptor tyrosine-based activating motif (ITAM)
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Figure 1. Time course of NAFT signal activation in Jurkat cell clones expressing TREM2DAP12 in the presence
of apoptotic cells. Equal numbers of apoptotic cells and Jurkat reporter cell clones expressing TREM2DAP12
were incubated for the indicated times (hours) and the luminescence of the cell lysates was measured. Data are
shown as means ± SD (n = 3). Where SDs are not shown, they are smaller than the symbols.
in the cytosolic domain. TREM2 is therefore postulated to bind ligands at its extracellular immunoglobulin
V-type domain and to transduce intracellular signals that regulate microglial functions such as cytokine production, migration, proliferation, phagocytosis, cell survival, synapse elimination, and compaction of amyloid plaques23,27–34. Notably, inflammatory cytokines are downregulated in Trem2-knockout mice30,31,33, and
anti-Trem2 agonistic antibody induces inflammatory cytokines in the brain35. These results suggest that TREM2
has a role in the production of inflammatory cytokines in vivo. Interestingly, a functional interaction between
TREM2 and familial AD gene presenilin 1 has been reported36. Proper signal transduction might be disturbed
by the risk-associated variants, leading to increased incidence of neurodegenerative disorders. Many proteins
or compounds that bind to the TREM2 extracellular domain have been reported, including phosphatidylserine
(PS), phosphatidylethanolamine (PE), phosphatidylcholine (PC), sulfoglycolipid, apolipoproteins, low-density
lipoprotein, high-density lipoprotein, heat shock protein 60, DNA, E. coli, apoptotic cells, and Aβ31,37–54. Among
them, apoptotic cells31,40, normal cultured cells39,40, and oligomeric Aβ53,54 have been confirmed to induce
TREM2-mediated intracellular signalling. However, the ligands expressed by apoptotic or normal cultured cells
have not been identified, and it is not clear whether other signal-transducing ligands of TREM2 are present in the
brain. In addition, further investigations are required to understand the different pathological effects of TREM2
variants on the signal transduction50.
In this work, we have developed a highly sensitive reporter cell model to monitor signal transduction from
TREM2, in order to identify the TREM2 ligands on apoptotic and normal cultured cells and to search for other
ligands in the brain that may be associated with increased incidence of AD. We found that the ligands expressed
on apoptotic Neuro2a cells, as well as some normal cultured cells, are aminophospholipids. Finally we suggest that
other TREM2 signal-transducing ligands are present in the membranes of mouse cerebral cortex.

Results

Establishment of reporter cell models for TREM2-dependent signal transduction. To establish
sensitive and specific reporter cell models to monitor TREM2 signal transduction, RAW264.7, 2B4, and Jurkat
cells were stably transfected with reporter genes: nuclear factor of activated T cells (NFAT) promoter element and
TREM2DAP12 fusion cDNA corresponding to TREM2 extracellular domain and DAP12 transmembrane and
cytosolic domain38,55,56. RAW264.7 was chosen because it is a macrophage cell line having similar characteristics
to microglia, such as phagocytosis and cytokine production. 2B4 and Jurkat cell lines were chosen because they
are derived from T cells, which are the only cell type so far shown to transduce signals via TREM231,37,40. These
reporter cells were incubated with apoptotic Neuro2a cells to induce signal transduction via TREM240 and luminescence or fluorescence of the cell lysates was measured. RAW264.7 reporter cells expressing TREM2DAP12
showed increased luminescence upon apoptotic cell treatment, but RAW264.7 cells not expressing TREM2DAP12
also showed increased luminescence, indicating that the signal is independent of exogenous TREM2DAP12 (not
shown). On the other hand, 2B4 reporter cells expressing TREM2DAP12 showed a 2- to 3-fold increase of fluorescence upon apoptotic cell treatment, while the parent 2B4 cells (control) did not (not shown). More strikingly,
Jurkat reporter cells expressing TREM2DAP12 showed a luminescence increase of more than 10-fold, while the
parent cells did not (see Figs 1 to 3). These results confirmed that apoptotic cells express TREM2 ligand(s) that
transduce an intracellular signal leading to NFAT activation31,40, and that T cell lines are suitable to study TREM2
signal transduction from apoptotic cells. In the following study, we used Jurkat reporter cells because of the high
signal-to-background ratio.
We first investigated the time course of the NFAT activation by apoptotic cells. As shown in Fig. 1, luminescence of Jurkat reporter cell clones expressing TREM2DAP12 began to increase at 6 hours and reached a plateau
at 14 hours when equal numbers of apoptotic cells and reporter cells were incubated. We then examined whether
or not the signal is TREM2-dependent. Reporter cell clones expressing TREM2DAP12 or TREM1DAP12 or
parent reporter cells (Fig. 2A) were incubated together with apoptotic cells, and the luminescence of the cell
lysates was measured. As shown in Fig. 2B, two independent reporter cell clones expressing TREM2DAP12
showed increased luminescence upon apoptotic cell treatment, while the parent reporter cells and two independent reporter cell clones expressing TREM1DAP12 did not, even though the amounts of TREM1DAP12
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Figure 2. Establishment of TREM2-dependent reporter cells. (A) Lysates of Jurkat reporter cell clones
expressing TREM1DAP12, TREM2DAP12 (11, 12, 48 and 80 indicate clone numbers) or parent reporter cells
(parent) were immunoblotted by anti-DAP12 antibody. (B) Apoptotic cells (apoptot. cells) and the Jurkat
reporter cell clones were incubated at a ratio of 1/2 and the luminescence of the cell lysates was measured. Data
are shown as means ± SD (n = 3). Two-tailed Student’s t test was performed. (C) Apoptotic cells and Jurkat
TREM2DAP12 reporter cell clones were incubated at a ratio of 1/10 together with anti-TREM2 antibodies and
the luminescence of the cell lysates was measured. Data are shown as means ± SD (n = 3). One-way ANOVA
with the Student-Newman-Keuls test was performed. ***p < 0.001.

Figure 3. TREM2 ligands are exposed at the cell surface upon apoptosis. (A) Apoptotic (closed circles) or
normal (open circles) Neuro2a cells and reporter cell clones expressing TREM2DAP12 were incubated with the
indicated ratio of Neuro2a: the reporter cell numbers and the luminescence of cell lysates were measured. Data
are shown as means ± SD (n = 3). Where SDs are not shown, they are smaller than the symbols. (B) Apoptotic
cells and reporter cell clones expressing TREM2DAP12 were incubated at a ratio of 1/10 with or without culture
inserts (0.4 μm pore size) and the luminescence of cell lysates was measured. Data are shown as means ± SD
(n = 4). One-way ANOVA with the Student-Newman-Keuls test was performed. *p < 0.05.
proteins expressed in the reporter cells were much greater than those of TREM2DAP12 proteins (Fig. 2A). All
of five independent TREM2DAP12-expressing cell clones that we established showed increased luminescence
in response to the apoptotic cells (not shown), although the efficacy of signal transduction was different in each
case. Moreover, anti-TREM2 antibody inhibited the reporter signal in a dose-dependent manner (Fig. 2C). These
results indicate that the signal transduced in the TREM2DAP12-expressing reporter cells exposed to apoptotic
cells is TREM2-dependent.

TREM2 ligands expressed on apoptotic cells are aminophospholipids.

Next, we examined the
characteristics of the TREM2 ligands expressed in apoptotic cells. We incubated the reporter cells with apoptotic
or normal cultured Neuro2a cells and measured the intensity of luminescence in the cell lysates. We found that
apoptotic Neuro2a cells transduced the signal in a dose-dependent manner, while normal cultured Neuro2a
cells transduced a signal similar to or weaker signal than that obtained with medium alone (Fig. 3A). When the
reporter cells and apoptotic cells were cultured without direct contact (separated by a culture insert membrane
with 0.4 μm pore size), the signal was almost completely blocked (Fig. 3B). These results suggest that TREM2
ligands are exposed on the cell surface upon apoptosis, and are not factors secreted from the cells.
These characteristics of TREM2 ligands are reminiscent of aminophospholipids, PS or PE, which are localized in the inner leaflet of the plasma membrane in intact cells, but become exposed when the cells are triggered to undergo apoptosis57. Recombinant protein MFGE8-L D89E, which retains the binding domain to
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Figure 4. TREM2 ligands on apoptotic cells are aminophospholipids. (A) MFGE8-L D89E proteins were
purified by anti-DDDDK antibody affinity column from culture media of HEK293 cells transfected with the
MFGE8-L D89E cDNA. The purified proteins were electrophoresed and visualized by silver staining. (B)
Apoptotic cells and reporter cell clones expressing TREM2DAP12 were incubated at a ratio of 1/10 together
with 1 μg/mL MFGE8-L D89E or BSA as a control, and the luminescence of the cell lysates was measured. Data
are shown as means ± SD (n = 3). One-way ANOVA with the Student-Newman-Keuls test was performed. (C)
The reporter cell clones expressing TREM2DAP12 were cultured in wells coated with purified PS, PE or PC and
the luminescence of the cell lysates was measured. Data are shown as means ± SD (n = 3). One-way ANOVA
with the Student-Newman-Keuls test was performed. ***p < 0.001.

aminophospholipids but cannot bind phagocytes expressing integrins 58, was purified to near homogeneity (Fig. 4A) and added to the culture medium of the reporter cells and apoptotic cells. As shown in Fig. 4B,
MFGE8-L D89E completely inhibited the signal induced by apoptotic cells, while control protein (BSA) did not.
This strongly indicated that the TREM2 ligands on the apoptotic cells are indeed aminophospholipids. In accordance with this observation, pure aminophospholipids PS and PE induced signal transduction in the reporter cells,
while PC, which is located on the exterior of intact cells, did not (Fig. 4C). The EC50 values for PS and PE could
not be determined because the reporter cells died before the luminescence reached a plateau in the presence of
higher concentrations of the lipids (not shown).

TREM2 ligands expressed on normal cultured cells are aminophospholipids. We then explored
whether or not normal cultured cell lines express signal-transducing ligands of TREM2, because some cultured
cell lines were shown to transduce NFAT signalling via TREM239,40. We incubated the reporter cells with various
cell lines and measured the luminescence. As shown in Fig. 5A normal cultured Jurkat and THP-1 cells induced
signal transduction in TREM2DAP12-expressing reporter cells although the strength of luminescence was much
less than that of apoptotic cells. This signal was TREM2-dependent, because TREM1DAP12-expressing reporter
cells showed no signal transduction (Fig. 5B). When MFGE8-L D89E protein was added to the cultures, the signal
was inhibited (Fig. 5C), suggesting that the TREM2 ligands on these normal cultured cells are also aminophospholipids, which might have become exposed during normal culture (see discussion).
TREM2 ligands expressed in the brain are not aminophospholipids. Finally, we searched for
TREM2 signal-transducing ligands in the brain. We incubated homogenates of cerebral cortices from young
adult mice (5 months old) with reporter cells expressing TREM2DAP12 and measured the luminescence. We
found that homogenates prepared from three independent mice increased the reporter activity (Fig. 6A) suggesting that the cerebral cortex contains ligand(s) that induce NFAT signalling via TREM2. This signal was
TREM2-dependent, because reporter cells expressing TREM1DAP12 (Fig. 6B) or parent control cells (not shown)
showed no signal. We then found that the ligands were present in the membrane fraction, not soluble fraction
of the homogenates (Fig. 6C). Unexpectedly, the signal induced by the membrane fraction was not inhibited by
MFGE8-L D89E (Fig. 6D); this result suggests that the ligands in the mouse cerebral cortical membranes are
different from aminophospholipids. To examine if the ligands are expressed by astrocytes, microglia or neurons,
we compared the TREM2 signal-inducing activity of cerebral cortices derived from wild-type and App knock-in
mice carrying NL-G-F mutations (AppNL-G-F)59, since the AppNL-G-F mice have increased numbers of astrocytes
and microglia in an aging-dependent manner after 6 months60. However, we found no significant difference of
TREM2 signal transduction between the two strains at 6 or 12 months (Fig. 6E) suggesting that the ligands might
not be expressed by astrocytes or microglia.

Discussion

We have established a highly sensitive and specific reporter cell model for TREM2 signal transduction in Jurkat
T cells. So far, two cell lines, BWZ and 2B4 T cells, have been reported as TREM2 signal-transducing cell models31,37,40. Hsieh et al. transfected both TREM2/DAP12 cDNAs in BWZ cells expressing lacZ gene under the
control of NFAT promoter, and Wang et al. introduced TREM2/DAP12 cDNAs in 2B4 cells stably expressing
EGFP under the control of NFAT promoter. In the presence of apoptotic cells, the BWZ and 2B4 reporter cells
showed about 4-fold and 1.2-fold increases of the reporter activity, respectively31,40. The Jurkat reporter cell model
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Figure 5. TREM2 ligands on normal cultured cells are aminophospholipids. (A) Various normal cultured cell
lines and reporter cell clones expressing TREM2DAP12 were incubated at a ratio of 1/1 and the luminescence
of the cell lysates was measured. Data are shown as means ± SD (n = 3). One-way ANOVA with the StudentNewman-Keuls test was performed. (B) Jurkat or THP-1 cell lines and reporter cell clones expressing
TREM1DAP12 were incubated at a ratio of 1/1 and the luminescence of the cell lysates was measured. Data are
shown as means ± SD (n = 3). (C) Jurkat or THP-1 cells and the reporter cell clones expressing TREM2DAP12
were incubated in a ratio of 1/1 together with 1 μg/mL MFGE8-L D89E and the luminescence of cell lysates was
measured. Data are shown as means ± SD (n = 3). One-way ANOVA with the Student-Newman-Keuls test was
performed. *p < 0.05; ***p < 0.001; #p < 0.01 compared to the non-treated reporter cells (white column).
established in this study is even more sensitive, as the luciferase activity was increased by more than 10-fold in the
presence of apoptotic cells (Figs 1 to 3). Possible reasons for this are that Jurkat cells may have greater amounts of
signalling molecules required for NFAT signal transduction via TREM2, or that TREM2DAP12 fusion proteins
are better able to transduce the signal than independently expressed TREM2 and DAP12. Another possibility
might be that the luc2P reporter gene used in this study has humanized codons, which may be favorable for
higher expression and reduced anomalous transcription. The luc2P gene also contains hPEST, a protein destabilization sequence, which allows luc2P protein levels to respond more quickly. A further advantage is that enzymatic
detection of the luc2P is faster (5 min) than that of LacZ40. In addition, the procedure is simpler than sorting
EGFP-expressing cells31, and is suitable for high-throughput screening of the agonists/antagonists. At the beginning of this study we tried to establish reporter cell models in RAW264.7 macrophage cell lines, but these cells
transduced the signal irrespective of overexpression of TREM2DAP12. Endogenous expression of TREM2 and
DAP12 in RAW264.7 cells61,62 might inhibit the signal from the overexpressed TREM2DAP12. As we and others
have shown, T cell lines are suitable models for TREM2 signal transduction, probably because T cells express little
endogenous TREM2 or DAP12 and share common signalling molecules with microglia, considering that T cell
receptors and DAP12 have the same ITAM at the cytoplasmic domains.
The Jurkat reporter cells expressing TREM2DAP12 transduced the signal when incubated with apoptotic
cells, while those expressing TREM1DAP12 did not (Fig. 2B), indicating the specificity of these reporter cells.
We speculate that ligand recognition involves specific amino acid residue(s) in TREM2. Identification of the
ligand-binding site in TREM2 would facilitate an understanding the interaction between TREM2 and the ligands, and would be helpful for drug development. The TREM2 antibody clone 237920 works as an antagonist of
the NFAT signal via TREM2 induced by apoptotic cells (Fig. 2C). This may suggest that the epitope of the antibody is located near the binding site to apoptotic cells. Thus, mapping of the epitope might help to identify the
ligand-binding site in TREM2. It would be interesting to see whether or not the epitope is identical to the reported
PS-binding site in TREM2 extracellular domain26.
Apoptotic cells transduce the NFAT signal via TREM231,40, while aminophospholipids such as PS and PE
also transduce the signal via TREM231,48. However, it has not been reported whether the TRME2 ligands in
apoptotic cells are aminophospholipids. In this study we established for the first time that the TREM2 ligands
in apoptotic cells are aminophospholipids by demonstrating inhibition of the signal with MFGE8 (Fig. 4B), an
aminophospholipid-binding protein that inhibits the interaction between apoptotic cells and phagocytes58. This
conclusion is supported by our findings that purified aminophospholipids (PS and PE), but not PC, transduce the
signal (Fig. 4C), and that direct binding between reporter cells and apoptotic cells is required for signal transduction (Fig. 3B), because aminophospholipids are exposed on the cell surface after apoptosis, while PC is already
exposed in healthy cells. Actually, Bailey reported that TREM2 binds to PS but not to PC45. However, other reports
suggested that PC might induce signal transduction via TREM231,48. The apparent contradiction may be due to
the different reporter cell systems used (2B4 cells in their studies vs. Jurkat cells in this study). Bader Lange et al.
reported that larger amounts of PS and PE are exposed on the surface of the synaptosomes in aged and AD model
mouse brain63, and this may increase TREM2 signal transduction, leading to expression of microglial protective
phenotypes. The increased incidence of AD associated with TREM2 R47H or R62H might be due to impaired
protection of the TREM2 signal during aging or AD progression resulting from loss of function50. Although we
still do not know exactly the target genes of TREM2 signal transduction responsible for the increased risk of AD,
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Figure 6. TREM2 ligands in membrane fractions of mouse cerebral cortex are not aminophospholipids.
(A) Homogenates of cerebral cortices from three 5-month-old mice (no. 1 to 3) and reporter cell clones
expressing TREM2DAP12 were incubated and the luminescence of cell lysates was measured. Data are shown as
means ± SD (n = 3). One-way ANOVA with the Student-Newman-Keuls test was performed. (B) Homogenates
of cerebral cortex from 5-month-old mice (no. 1 to 3) and reporter cell clones expressing TREM1DAP12
were incubated and the luminescence of cell lysates was measured. Data are shown as means ± SD (n = 3). (C)
Homogenates, soluble fraction or membrane fraction of the cerebral cortex and reporter cell clones expressing
TREM2DAP12 were incubated and the luminescence of the cell lysates was measured. Data are shown as
means ± SD (n = 3). One-way ANOVA with the Student-Newman-Keuls test was performed. (D) Membrane
fractions of the cerebral cortex and reporter cell clones expressing TREM2DAP12 were incubated together with
1 μg/mL MFGE8-L D89E or BSA and the luminescence of the cell lysates was measured. Data are shown as
means ± SD (n = 3). **p < 0.01; ***p < 0.001; n.s. not significant. (E) Homogenates of cerebral cortices from 6and 12-month wild-type and AppNL-G-F knock-in mice and reporter cell clones expressing TREM2DAP12 were
incubated and the luminescence of cell lysates was measured. Luminescence of the reporter cells incubated with
the buffer alone is shown as a broken line. Data are means ± SE (n = 3), and compared using Student’s t test. n.s.
not significant.
genes encoding factors involved in mTOR activation, which controls energetic and anabolic metabolism, might
be candidates64. Further study will be needed to understand the link between TREM2 signal transduction and AD
pathogenesis at the molecular level.
Our results indicate that the TREM2 ligands on normal cultured Jurkat and THP-1 cells are aminophospholipids (Fig. 5C). We hypothesize that small amounts of cells might die spontaneously during normal culture,
resulting in exposure of previously inaccessible aminophospholipids. Since TREM2DAP12-expressing reporter
cells are derived from Jurkat cells, aminophospholipids exposed on small amounts of the dying reporter cells
might transduce the NFAT signal by themselves. Indeed, MFGE8 reduced the reporter activity to less than that
of the normal cultured reporter cells (compare 3rd and 5th columns with 1st column in Fig. 5C), supporting this
hypothesis. Unknown TREM2 ligands on normal cultured cells that transduce the NFAT signal were previously
reported39,40. Our results suggest that those unidentified ligands might be aminophospholipids.
Finally, we showed that TREM2 ligands that can specifically transduce intracellular signalling are present in
the membrane fractions of 5-month-old mouse cerebral cortex, and that MFGE8 protein does not inhibit the
signal (Fig. 6), suggesting that the signal-transducing ligands in the mouse brain are different from aminophospholipids. However, it is not clear why aminophospholipids, which should be present in the membrane fractions,
cannot transduce the signal. One possible explanation would be that signal-transducing ligands in the brain may
have a higher affinity for TREM2 than aminophospholipids, thus excluding the signal from aminophospholipids.
Since nuclear and soluble fractions were removed from the membrane fractions, DNA and RNA can be excluded
as candidates for the endogenous signal-transducing ligands. Subtle quantitative or qualitative alterations of the
ligands might occur in the brain during aging, resulting in an increase in the incidence of AD. The TREM2
signal-inducing activities in the cerebral cortex from wild-type and AppNL-G-F knock-in mice were not significantly different (Fig. 6E), suggesting that the ligands might not be derived from astrocytes or from microglia,
considering that the numbers of astrocytes and microglia are robustly increased after 6 months in AppNL-G-F
knock-in mice60. Thus, the ligands might be expressed by live neurons. Identification of the ligands in the cortices
will be an important next step for understanding the functional interaction between microglia and neurons, as
well as the relevance of TREM2 to the development of neurodegenerative disorders. It would also be interesting
to investigate whether AD-related variants such as R47H affect the binding and/or signal transduction from the
ligands in the mouse cerebral cortex, and we are currently comparing the signal transduction characteristics of
reporter cell clones expressing wild-type TREM2DAP12 and R47H variant.
In sum, we have developed a highly sensitive reporter cell model for signal transduction via TREM2 and
showed that the TREM2 ligands on apoptotic and normal cells are aminophospholipids. The model should be
useful to examine signal transduction by apolipoprotein E or oligomeric Aβ and to investigate the effects of
TREM2 variants on the signal transduction.
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Methods
cDNAs.

Human TREM265 and mouse MFGE8-L D89E58 cDNAs were as described. Human TREM1 and
DAP12 cDNAs were obtained from Kazusa DNA Research Institute (Chiba, Japan) and Health Science Research
Resources Bank (Osaka, Japan), respectively. cDNAs encoding the extracellular domain of TREM1 (amino acid
residue 1-203) and TREM2 (amino acid residue 1-172) were amplified, fused with the transmembrane and cytosolic domain of human DAP12 (amino acid residues 30-113) with its stop codon by PCR, and inserted into
the NheI and XhoI sites of pEBMulti-Neo TARGET tag-C (Fuji Film, Osaka, Japan). pGL4.30[luc2P/NFAT-RE/
Hygro] vector (Promega, Madison, WI, USA) was used as a reporter gene, containing the luciferase reporter gene
luc2P (Photinus pyralis) under the control of NFAT-responsive element.

Culture cells.

Jurkat human T cells, 2B4 mouse T cell hybridoma cells, and THP-1 human monocytes were
maintained in RPMI1640 media (Fuji Film) supplemented with 10% fetal bovine serum (Sigma-Aldrich, St.
Louis, MO, USA) and penicillin/streptomycin (Fuji Film). RAW264.7 mouse macrophages, HEK293 human
embryonic kidney cells, and Neuro2a mouse neuroblastoma cells were maintained in DMEM (Fuji Film) supplemented with 10% fetal bovine serum and penicillin/streptomycin.

Reporter cells.

Jurkat cells were transfected with pGL4.30[luc2P/NFAT-RE/Hygro] in a NEPA21 super
electroporator (Nepa Gene Corporation, Ltd., Chiba, Japan) and stably transfected clones were selected with
0.4 mg/mL hygromycin B (Fuji Film), followed by limiting dilution. Then, the cell clones were transfected with
TREM2DAP12 (or TREM1DAP12) cDNA and stably transfected clones were selected with 1 mg/mL G418 (Fuji
Film), followed by limiting dilution.
RAW264.7 cells were transfected with pGL4.30[luc2P/NFAT-RE/Hygro] using Lipofectamine2000 (Thermo
Fisher Scientific, Waltham, MA, USA), and selected with 0.4 mg/mL hygromycin B. The cell clones were transfected with TREM2DAP12 cDNA and selected with 1 mg/mL G418.
2B4 cells stably transfected with enhanced green fluorescent protein (EGFP) gene under the control of
NFAT-responsive element66 were transfected with TREM2DAP12 cDNA using a NEPA21 super electroporator
and selected with 1 mg/mL G418.

Western blot analysis. Cell lysates were extracted with lysis buffer (1% Triton-X 100, protease inhibitor cocktail (CompleteTM, Roche Diagnostics, Indianapolis, IN, USA), 700 ng/ml pepstatin A (Peptide Institute, Osaka,
Japan) in phosphate-buffered saline). Aliquots were electrophoresed on 10% polyacrylamide sodium dodecyl
sulfate-gel and blotted onto polyvinylidene difluoride membrane (HybondTM-P, Amersham Biosciences, Piscataway,
NJ, USA). The membranes were probed with anti-DAP12 antibodies (Santa Cruz (Dallas, TX, USA)), followed
by HRP-conjugated secondary antibodies IgG (Cell Signalling technology, Danvers, MA, USA). Immunoreactive
bands were visualized with ImmunoStar LD (Fuji Film) and detected on a LAS-4000 mini (Fuji Film).
Reporter assay. Neuro2a cells were treated with 100 nM staurosporin (Fuji Film) overnight to induce
apoptosis, then washed and resuspended in the culture media. The apoptotic Neuro2a cells and 1 × 105
Jurkat reporter cells were incubated at 37 °C in a ratio of 1/16 to 2/1 in 48-well plates for 14 hours, unless
otherwise indicated. The cell lysates were incubated with One-Glo TM reagent (Promega) in a 384-well
plate for 5 min, and the luminescence was measured with a SPARK 20 M (Tecan, Männedorf, Switzerland).
Normal cultured Neuro2a, Jurkat, THP-1, RAW264.7, and HEK293 cells were collected by pipetting or
with TrypLE Select CTS (Thermo Fisher Scientific) and resuspended in the culture media after centrifugation. Where indicated, anti-TREM2 antibody (clone 237920, R&D Systems, Minneapolis, MN,
USA), purified milk fat globule-EGF factor 8 (MFGE8)-L D89E, or bovine serum albumin (BSA) (Takara
Bio, Osaka, Japan) was added to the culture media. Culture inserts with 0.4 μm pore membrane (Thermo
Fisher Scientific) were used to block direct interaction between the apoptotic cells and reporter cells.
Phosphatidylserine (PS), phosphatidylethanolamine (PE) and phosphatidylcholine (PC) (Sigma-Aldrich)
were dissolved in methanol and coated on plates by drying before the reporter cells were seeded. Homogenates
of cerebral cortices from wild-type and App NL-G-F knock-in 59 mice were prepared by homogenization in
buffer (50 mM Tris-HCl buffer (pH 7.4), 150 mM NaCl, protease inhibitor cocktail, 0.7 ug/ml pepstatin A).
The homogenates were centrifuged at 800 g for 10 min at 4 °C to remove nuclei and cell debris, and the post
nuclear supernatants were centrifuged at 70,000 rpm in a TLA110 rotor (Beckman Coulter Diagnosis, Brea,
CA, USA) for 29 min at 4 °C. The supernatants (soluble proteins) and resuspended membrane pellets were
incubated with the reporter cells. All experiments conducted here were approved by the Ethics Committees of
Nagasaki University.

™

™

Preparation of MFGE8-L D89E protein.

HEK293 cells were transfected with MFGE8-L D89E cDNA58
using Lipofectamine3000 (Thermo Fisher Scientific). After 24 hours, the medium was replaced with DMEM without fetal bovine serum and the cells were further cultured for 30 hours. MFGE8-L D89E protein in the culture
media was purified with anti-DDDDK-tag mAb-Magnetic Beads (MBL, Aichi, Japan) and subjected to silver
staining (Silver Stain MS kit (Fuji Film).

Statistical analysis. Statistical analysis was done by SigmaPlot software, ver.14.0 (Systat Software Inc., San
Jose, CA). To compare two groups, a two-tailed Student’s t test was employed after confirming equality of variances
of the groups. To compare more than two groups, we used one-way ANOVA with the Student-Newman-Keuls
test. P values of less than 0.05 were considered to be significant.
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